Allogeneic Peripheral Blood Stem Cell Transplant — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for allogeneic peripheral blood stem cell transplant. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
2
Active US patents
93/100
Avg vulnerability
—
Annual revenue covered

Originators in Allogeneic Peripheral Blood Stem Cell Transplant

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Medexus 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating allogeneic peripheral blood stem cell transplant. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
26

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Trecondi
TREOSULFAN
 Medexus 2 93 — 2026-10-12

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7199162 Trecondi method of use 93 2026-10-12
7199162 Trecondi method of use 93 2026-10-12

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7199162 Trecondi method of use 93 2026-10-12
7199162 Trecondi method of use 93 2026-10-12

Related